GlobeNewswire

Interim Report Q3 2026: Successful product launches leading to 2% organic revenue growth and margin expansion
05/11/2026
Highlights The Enterprise division delivered organic revenue growth of 1%, following positive market reception of the second wave of the Evolve3 launch. The development reflects continued solid performance in North [...]
Zelluna ASA: Third Quarter 2026 results
05/11/2026
Oslo, 5 November 2026 – Zelluna (OSE: ZLNA), a clinical-stage company pioneering allogeneic "off-the-shelf" T Cell Receptor-based Natural Killer (TCR-NK) cell therapies for the treatment of solid cancers, today presents [...]
IBA signe un contrat avec le gouvernement de l’État de l’Assam pour le premier centre public de protonthérapie en Inde
05/11/2026
Ce projet marque une étape importante pour élargir l’accès aux traitements de pointe contre le cancer en Inde Louvain-la-Neuve, Belgique, le 5 novembre 2026, 7h00 CET – IBA (Ion Beam Applications S.A., EURONEXT), leader [...]
IBA signs contract with the Government of Assam for India’s First State-run Proton Therapy Center
05/11/2026
The project in Assam marks an important milestone in expanding access to advanced cancer care in India Louvain-La-Neuve, Belgium, November 05, 2026 at 7 a.m. CET – IBA (Ion Beam Applications S.A., EURONEXT), the world [...]
Q3 2026 Update: Tecan reports acceleration of sales growth in Q3 and raises full-year 2026 outlook
05/11/2026
Ad hoc announcement pursuant to Article 53 of the SIX Exchange Regulation Listing Rules Q3 2026 Update: Tecan reports acceleration of sales growth in Q3 and raises full-year 2026 outlook Männedorf, Switzerland, November [...]
Vivoryon Therapeutics N.V. Reports Q3 2026 Financial Results and Provides Business Update
05/11/2026
Vivoryon Therapeutics N.V. Reports Q3 2026 Financial Results and Provides Business Update Ongoing negotiations with different parties towards securing a partnership or financing for the development of varoglutamstat in [...]
Siemens Healthineers to Rebrand In Vitro Diagnostics Business as Olyrian Diagnostics
05/11/2026
Siemens Healthineers announced today it has initiated the carve-out process for its in vitro diagnostics business Tarrytown, New York, USA, Nov. 05, 2026 (GLOBE NEWSWIRE) -- The company is preparing its Diagnostics [...]
ANI Pharmaceuticals Announces Offer to Acquire Egetis Therapeutics, Expanding the Scope and Scale of Its Rare Disease Business
05/11/2026
Egetis Therapeutics’ lead asset, EMCITATE ® , is the first and only approved treatment in U.S. and Europe for peripheral thyrotoxicosis associated with MCT8 deficiency, a rare genetic disorder, impacting approximately 1 [...]
Interim report 9M 2026
05/11/2026
Strong Q3 sales leading to 9M at 7% organic sales growth and adj. EBITDA margin of 37.9%. 2026 outlook confirmed: 7-8% organic sales growth and adj. EBITDA margin at the higher end of the 37-38% range. Ester Baiget, [...]
T-Therapeutics announces oversubscribed $133 million Series B financing to achieve clinical proof-of-concept for first-in-class TCR bispecific therapies in cancer and autoimmune disease
05/11/2026
$133 million Series B financing co-led by new investors Advent Life Sciences and British Business Bank, with additional new investments from Johnson & Johnson Innovation – JJDC, Inc. (JJDC), Samsara BioCapital, M- [...]
Ascentage Pharma to Present Data from Multiple Trials, Including an Oral Presentation of APG-5918 at ASH 2026
05/11/2026
ROCKVILLE, Md., Nov. 04, 2026 (GLOBE NEWSWIRE) -- Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855), a global, commercial-stage, integrated biopharmaceutical company engaged in the discovery, development, [...]
HUTCHMED Announces Sovleplenib Granted US FDA Orphan Drug Designation for Autoimmune Hemolytic Anemia
05/11/2026
— Eligible for development incentives including 7 years of US market exclusivity upon regulatory approval — — Marks the second US FDA Orphan Drug Designation for sovleplenib, following its recent designation for primary [...]
TaiMed Biologics to Present 24-Week Phase 2a Data on TMB-365/TMB-380 Maintenance Regimen at HIV Glasgow 2026
05/11/2026
Company will present results from a Phase 2a study of TMB-365/TMB-380 administered every eight weeks as maintenance therapy in virologically suppressed people living with HIV-1, along with an encore poster on its Phase [...]
Use Of Ryoncil First Line After Steroids For Pediatric Acute Graft Versus Host Disease Highlighted In Key Opinion Leader Webinar
05/11/2026
NEW YORK, Nov. 04, 2026 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, announced that it hosted a key opinion leader webinar this [...]
Step Pharma to present data from ongoing phase 2 clinical trial of dencatistat in essential thrombocythaemia at 68th ASH Annual Meeting
05/11/2026
First presentation of clinical data from ET programme demonstrating a consistent and clinically meaningful platelet control with favourable tolerability profile VECTRA trial will enrol up to 50 participants with high- [...]
Cloudbreak Pharma Announces Top-Line Results from its Phase 3 Study of CBT-001 in Patients with Pterygium
05/11/2026
Both doses of CBT-001 demonstrated statistically significant improvements in conjunctival hyperemia at Month 3 versus vehicle (p<0.001), with improvement observed as early as Week 2 and maintained through Month 12 [...]
Baird Medical Issues Statement Regarding Recent Share Price Volatility
04/11/2026
NEW YORK, Nov. 04, 2026 (GLOBE NEWSWIRE) -- Baird Medical Investment Holdings Limited (NASDAQ: BDMD) (“Baird Medical” or the “Company”), a healthcare innovator dedicated to microwave ablation (MWA) technology, has [...]
Revolution Medicines Reports Third Quarter 2026 Financial Results and Update on Corporate Progress
04/11/2026
Received U.S. FDA approval and launched RASONQUE ® (daraxonrasib) for adult patients with metastatic pancreatic cancer who have received at least one prior systemic therapy or who are not candidates for multiagent [...]
Agomab to Participate in Upcoming Investor Conferences
04/11/2026
Antwerp, Belgium, November 4, 2026 – Agomab Therapeutics NV (Nasdaq: AGMB) (“Agomab”), a clinical-stage biopharmaceutical company focused on fibro-inflammation, today announced that members of the management team will [...]

Pages

Other news

Test 2

Lorem ipsum

Test 1

Lorem upsum